Scarica l'app Stockscreener
34.93
1.51%
0.52
Dopo l'orario di chiusura:
35.31
0.38
+1.09%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché ROIV Giù?
Forum
Previsione
Precedente Chiudi:
$34.41
Aprire:
$34.2
Volume 24 ore:
5.24M
Relative Volume:
0.89
Capitalizzazione di mercato:
$25.23B
Reddito:
$8.26M
Utile/perdita netta:
$-397.91M
Rapporto P/E:
-69.36
EPS:
-0.5036
Flusso di cassa netto:
$-758.56M
1 W Prestazione:
+0.63%
1M Prestazione:
+0.98%
6M Prestazione:
+18.33%
1 anno Prestazione:
+177.88%
Intervallo 1D:
$33.88
$35.15
Intervallo di 1 settimana:
$33.43
$35.34
Portata 52W:
$12.54
$37.97
Roivant Sciences Ltd Stock (ROIV) Company Profile
Nome
Roivant Sciences Ltd
Settore
Industria
Telefono
441-295-5950
Indirizzo
7TH FLOOR, 50 BROADWAY, LONDON
Compare ROIV vs VRTX, REGN, ARGX, MRNA, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ROIV
Roivant Sciences Ltd
|
34.93 | 26.61B | 8.26M | -397.91M | -758.56M | -0.5036 |
VRTX
Vertex Pharmaceuticals Inc
|
546.12 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
827.72 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,033.15 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
145.55 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
210.02 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Roivant Sciences Ltd Stock (ROIV) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-03-20 | Iniziato | Bernstein | Outperform |
| 2025-09-02 | Iniziato | Citigroup | Buy |
| 2025-07-10 | Ripresa | Goldman | Buy |
| 2024-02-15 | Iniziato | Wolfe Research | Outperform |
| 2024-01-05 | Iniziato | Piper Sandler | Overweight |
| 2023-12-12 | Iniziato | Deutsche Bank | Buy |
| 2023-10-17 | Iniziato | Guggenheim | Buy |
| 2023-06-08 | Iniziato | BofA Securities | Neutral |
| 2022-10-27 | Iniziato | JP Morgan | Overweight |
| 2022-05-23 | Iniziato | SVB Leerink | Outperform |
| 2022-04-29 | Iniziato | Cantor Fitzgerald | Overweight |
| 2021-12-15 | Iniziato | Goldman | Buy |
| 2021-11-08 | Iniziato | H.C. Wainwright | Buy |
| 2021-10-28 | Iniziato | Citigroup | Buy |
| 2021-10-26 | Iniziato | Cowen | Outperform |
| 2021-10-26 | Iniziato | Jefferies | Buy |
| 2021-10-26 | Iniziato | Truist | Buy |
Mostra tutto
Roivant Sciences Ltd Borsa (ROIV) Ultime notizie
Roivant (NASDAQ: ROIV) CIO sells option shares near $37 - Stock Titan
ROIV Stock Nears Record High –Retail Traders See Breakout After Surprise Earnings Beat - Stocktwits
107,786 Shares in Roivant Sciences Ltd. $ROIV Purchased by Great Lakes Advisors LLC - MarketBeat
Is Roivant Sciences (ROIV) Fully Valued As First Quarter Results Show A Narrower Loss? - Sahm
Roivant Sciences (ROIV) holder plans new sale after $17M June trade - Stock Titan
Roivant Sciences Insider Sold Shares Worth $24,160,402, According to a Recent SEC Filing - marketscreener.com
Roivant President, CIO Mayukh Sukhatme disposes of USD 24.12 million in common shares - Bitget
Roivant Sciences (NASDAQ:ROIV) Insider Mayukh Sukhatme Sells 243,177 Shares - MarketBeat
Mayukh Sukhatme Sells 284,707 Shares of Roivant Sciences (NASDAQ:ROIV) Stock - MarketBeat
Roivant (ROIV) CIO sells shares after exercising $3.85 options - Stock Titan
Roivant Sciences Ltd. (NASDAQ:ROIV) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat
Roivant Sciences stock hits all-time high at 37.06 USD By Investing.com - Investing.com Australia
Roivant (NASDAQ: ROIV) holder eyes new sale after tens of millions sold - Stock Titan
Roivant Sciences (ROIV) Holds Steady at $36.2 as Shares Consolidate Between Support and ResistanceDefined Outcome ETF - vinanet.vn
Roivant Sciences (NASDAQ:ROIV) Sets New 1-Year HighHere's Why - MarketBeat
Roivant Sciences stock hits all-time high at 37.06 USD - Investing.com
Why Is Roivant (NASDAQ:ROIV) in NASDAQ Composite Focus Before Results? - Kalkine Media
Why Is Roivant (NASDAQ:ROIV) a Nasdaq Healthcare Stock to Watch? - Kalkine Media
Roivant Sciences Ltd. (ROIV) Stock Analysis: Exploring a 15.52% Upside Potential with Strong Buy Ratings - DirectorsTalk Interviews
Roivant Sciences Ltd (ROIV) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
How Investors May Respond To Roivant Sciences (ROIV) Narrowing Losses Despite Weaker Quarterly Revenue - simplywall.st
Royal Bank of Canada Decreases Position in Roivant Sciences Ltd. $ROIV - MarketBeat
Empowered Funds LLC Buys 267,686 Shares of Roivant Sciences Ltd. $ROIV - MarketBeat
Handelsbanken Fonder AB Has $6.27 Million Position in Roivant Sciences Ltd. $ROIV - MarketBeat
9 Health Care Stocks Whale Activity In Today’s Session - Benzinga
Roivant Sciences Ltd. (ROIV) Stock Forecasts - Yahoo Finance
How Roivant Sciences Ltd. (ROIV) Affects Rotational Strategy Timing - Stock Traders Daily
Roivant Sciences Ltd. (ROIV) Stock Price, News, Quote & History - Yahoo! Finance Canada
Roivant Sciences Ltd (ROIV) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Citi Maintains Roivant Sciences(ROIV.US) With Buy Rating, Raises Target Price to $46 - Moomoo
Roivant Sciences (ROIV) Is Up 7.2% After Narrower Net Loss Despite Lower Quarterly Revenue - webull.com
J.P. Morgan Maintains Roivant Sciences(ROIV.US) With Buy Rating, Maintains Target Price $40 - Moomoo
Roivant Sciences Ltd. (ROIV) Stock Analysis: Strong Buy Ratings And 15% Upside Potential - DirectorsTalk Interviews
Is Roivant Sciences’ (ROIV) Cost Discipline Offsetting Slower Revenue Enough to Refresh Its Story? - Yahoo Finance
Is Roivant Sciences (ROIV) Overvalued On First Quarter Results? - Yahoo Finance
Bank of America Corp DE Has $87.64 Million Stock Position in Roivant Sciences Ltd. $ROIV - MarketBeat
Roivant Sciences: The Balance Sheet Has Become A Strategic Weapon - Seeking Alpha
Sei Investments Co. Acquires 33,508 Shares of Roivant Sciences Ltd. $ROIV - MarketBeat
Roivant Sciences (ROIV) Stock Rally Leans On Cash As Losses Persist - simplywall.st
Piper Sandler Maintains Roivant Sciences(ROIV.US) With Buy Rating, Maintains Target Price $40 - Moomoo
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
Guggenheim Issues Positive Forecast for Roivant Sciences (NASDAQ:ROIV) Stock Price - MarketBeat
Roivant Sciences Ltd (ROIV) Stock News Today - TradingKey
Guggenheim Maintains Roivant Sciences(ROIV.US) With Buy Rating, Raises Target Price to $42 - Moomoo
Roivant Sciences Ltd. Q1 2026 Earnings Call Summary - finance.yahoo.com
Roivant Sciences Q1 Earnings Call Highlights - MarketBeat
Assenagon Asset Management S.A. Acquires 1,286,464 Shares of Roivant Sciences Ltd. $ROIV - MarketBeat
TD Cowen raises Roivant Sciences stock price target to $50 on execution - Investing.com South Africa
Roivant Sciences Ltd. Stock 12‑Month Price Target Raised to $39.73, Implies 15% Upside - TradingView
Earnings call transcript: Roivant posts Q1 2026 EPS beat, revenue miss as shares slip - Investing.com Nigeria
Roivant Sciences earnings beat by $0.04, revenue fell short of estimates - Investing.com
Roivant Sciences Ltd Azioni (ROIV) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Roivant Sciences Ltd Azioni (ROIV) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Venker Eric | President & Immunovant CEO |
Aug 28 '26 |
Sale |
35.77 |
200,000 |
7,153,393 |
1,599,154 |
0.86%
0.31%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):